Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

NCT00789685 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lung Injury
Acute Respiratory Distress Syndrome

Interventions

DRUG: Interferon Beta

Sponsor

Faron Pharmaceuticals Ltd